BDX Stock Overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Becton Dickinson Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$228.34|
|52 Week High||US$280.62|
|52 Week Low||US$227.25|
|1 Month Change||-10.01%|
|3 Month Change||-8.42%|
|1 Year Change||-8.57%|
|3 Year Change||-8.90%|
|5 Year Change||17.87%|
|Change since IPO||2,816.92%|
Recent News & Updates
BD, Certest Biotec launch monkeypox test
Becton, Dickinson (NYSE:BDX) and partner CerTest Biotec said on Monday their molecular polymerase chain reaction (PCR) assay for monkeypox virus was now commercially available globally, including in the United States, for research use only applications by laboratories. BD said it was working to submit a clinical test for monkeypox virus for emergency used authorization by the U.S. Food and Drug Administration as soon as possible. The CerTest Viasure Monkeypox virus PCR Detection RUO assay for the BD MAX System is offered in a lyophilized format. The BD MAX System is a platform that performs nucleic acid extraction and real-time PCR that provide results for up to 24 samples across multiple syndromes in less than three hours.
Becton, Dickinson launches next-gen prefillable vaccine syringe BD Effivax
Becton, Dickinson and Company (NYSE:BDX) said it launched a next-generation glass prefillable syringe (PFS) for vaccine PFS with tightened specifications for processability and contamination. BD Effivax is designed in collaboration with pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing, the company said in a Sept. 13 press release. "As biopharmaceutical companies continue to rapidly grow their vaccine pipelines, demand for PFS is accelerating across the globe – given their proven ability to facilitate faster administration, support dose sparing and reduce vaccine waste," said Eric Borin, Worldwide President of BD Pharmaceutical Systems.
Becton, Dickinson ordered to pay $4.8M in hernia mesh trial – Bloomberg
A jury on Friday concluded that health equipment maker Becton, Dickinson (NYSE:BDX) must award $4.8M as damages to a man who claimed that a hernia mesh sold by one of its units damaged his bowels, impairing his ability to work, Bloomberg reported Monday. The verdict issued in state court in Providence, Rhode Island, on Monday relates to BDX’s Ventralex hernia-mesh kit sold by the company’s Davol unit. The decision follows a case brought by a municipal worker in Hawaii who claimed that the company defectively designed the product and did not properly warn about its health risks., Bloomberg reported quoting his attorney Jonathan Orent. In April, an Ohio jury ordered BDX to pay $255K as damages to man in a similar trial over hernia mesh products.
|BDX||US Medical Equipment||US Market|
Return vs Industry: BDX exceeded the US Medical Equipment industry which returned -32.3% over the past year.
Return vs Market: BDX exceeded the US Market which returned -23.7% over the past year.
|BDX Average Weekly Movement||3.0%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BDX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BDX's weekly volatility (3%) has been stable over the past year.
About the Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
Becton Dickinson Fundamentals Summary
|BDX fundamental statistics|
Is BDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BDX income statement (TTM)|
|Cost of Revenue||US$10.59b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||6.66|
|Net Profit Margin||9.46%|
How did BDX perform over the long term?See historical performance and comparison
1.5%Current Dividend Yield
Is BDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BDX?
Other financial metrics that can be useful for relative valuation.
|What is BDX's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does BDX's PE Ratio compare to its peers?
|BDX PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ISRG Intuitive Surgical
BSX Boston Scientific
EW Edwards Lifesciences
BDX Becton Dickinson
Price-To-Earnings vs Peers: BDX is good value based on its Price-To-Earnings Ratio (34.3x) compared to the peer average (46.1x).
Price to Earnings Ratio vs Industry
How does BDX's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Earnings vs Industry: BDX is expensive based on its Price-To-Earnings Ratio (34.3x) compared to the US Medical Equipment industry average (32x)
Price to Earnings Ratio vs Fair Ratio
What is BDX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||34.3x|
|Fair PE Ratio||38.9x|
Price-To-Earnings vs Fair Ratio: BDX is good value based on its Price-To-Earnings Ratio (34.3x) compared to the estimated Fair Price-To-Earnings Ratio (38.9x).
Share Price vs Fair Value
What is the Fair Price of BDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BDX ($228.34) is trading below our estimate of fair value ($378.5)
Significantly Below Fair Value: BDX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Becton Dickinson forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDX's forecast earnings growth (15.7% per year) is above the savings rate (1.9%).
Earnings vs Market: BDX's earnings (15.7% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: BDX's earnings are forecast to grow, but not significantly.
Revenue vs Market: BDX's revenue (4.8% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: BDX's revenue (4.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BDX's Return on Equity is forecast to be low in 3 years time (15.1%).
Discover growth companies
How has Becton Dickinson performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BDX has a large one-off loss of $546.0M impacting its June 30 2022 financial results.
Growing Profit Margin: BDX's current net profit margins (9.5%) are higher than last year (7.8%).
Past Earnings Growth Analysis
Earnings Trend: BDX's earnings have grown significantly by 29.2% per year over the past 5 years.
Accelerating Growth: BDX's earnings growth over the past year (27.9%) is below its 5-year average (29.2% per year).
Earnings vs Industry: BDX earnings growth over the past year (27.9%) exceeded the Medical Equipment industry 0.6%.
Return on Equity
High ROE: BDX's Return on Equity (7.8%) is considered low.
Discover strong past performing companies
How is Becton Dickinson's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BDX's short term assets ($9.5B) exceed its short term liabilities ($7.1B).
Long Term Liabilities: BDX's short term assets ($9.5B) do not cover its long term liabilities ($20.6B).
Debt to Equity History and Analysis
Debt Level: BDX's net debt to equity ratio (54.1%) is considered high.
Reducing Debt: BDX's debt to equity ratio has reduced from 151% to 64.2% over the past 5 years.
Debt Coverage: BDX's debt is not well covered by operating cash flow (16%).
Interest Coverage: BDX's interest payments on its debt are well covered by EBIT (8.1x coverage).
Discover healthy companies
What is Becton Dickinson current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Becton Dickinson Dividend Yield vs Market|
|Company (Becton Dickinson)||1.5%|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Medical Equipment)||1.9%|
|Analyst forecast in 3 Years (Becton Dickinson)||1.8%|
Notable Dividend: BDX's dividend (1.52%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.67%).
High Dividend: BDX's dividend (1.52%) is low compared to the top 25% of dividend payers in the US market (4.68%).
Stability and Growth of Payments
Stable Dividend: BDX's dividends per share have been stable in the past 10 years.
Growing Dividend: BDX's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (51.7%), BDX's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (67.7%), BDX's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Polen (49 yo)
Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Co...
CEO Compensation Analysis
|Tom Polen's Compensation vs Becton Dickinson Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||US$14m||US$1m|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||US$12m||US$952k|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||US$6m||US$900k|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||US$6m||US$850k|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||US$4m||US$761k|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||US$3m||US$651k|
Compensation vs Market: Tom's total compensation ($USD14.19M) is about average for companies of similar size in the US market ($USD13.05M).
Compensation vs Earnings: Tom's compensation has increased by more than 20% in the past year.
Experienced Management: BDX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: BDX's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|06 May 22||SellUS$121,600||David Hickey||Individual||475||US$256.00|
|08 Feb 22||SellUS$228,500||Claire Fraser-Liggett||Individual||841||US$271.70|
|16 Dec 21||SellUS$711,195||Betty Larson||Individual||2,789||US$255.00|
|07 Dec 21||SellUS$58,250||Thomas Spoerel||Individual||233||US$250.00|
|Owner Type||Number of Shares||Ownership Percentage|
|State or Government||131,751||0.05%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Becton, Dickinson and Company's employee growth, exchange listings and data sources
- Name: Becton, Dickinson and Company
- Ticker: BDX
- Exchange: NYSE
- Founded: 1897
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$65.121b
- Shares outstanding: 285.20m
- Website: https://www.bd.com
Number of Employees
- Becton, Dickinson and Company
- 1 Becton Drive
- Franklin Lakes
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BDX||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|BOX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|BOX||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1968|
|912061||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Jan 1968|
|0R19||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|BDX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|BDX||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|BOX||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|B1DX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 5 REPR 1 COM||BR||BRL||Jan 2020|
|BDXB||NYSE (New York Stock Exchange)||6% DP CONV PFD B||US||USD||May 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/27 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.